Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib in Hematologic Malignancies
NCT04728893Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of nemtabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter's transformation (RT), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), sponsored by Merck & Co.. Started Apr 2021; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Richter's transformation (RT)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04728893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728893.